Vitt Revenue and Competitors
Estimated Revenue & Valuation
- Vitt's estimated annual revenue is currently $105k per year.
- Vitt's estimated revenue per employee is $21,000
- Vitt's total funding is $15M.
Employee Data
- Vitt has 5 Employees.
- Vitt grew their employee count by -17% last year.
Vitt's People
Name | Title | Email/Phone |
---|---|---|
1 | Head Finance and Capital Markets | Reveal Email/Phone |
Vitt Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $106.8M | 407 | -12% | N/A | N/A |
#2 | $220.4M | 734 | -1% | $13.6M | N/A |
#3 | $23.1M | 110 | -2% | N/A | N/A |
#4 | $727.9M | 2476 | 10% | N/A | N/A |
#5 | $40M | 173 | 20% | N/A | N/A |
#6 | $26.7M | 127 | 4% | N/A | N/A |
#7 | $19.1M | 91 | -12% | N/A | N/A |
#8 | $11.2M | 59 | 5% | N/A | N/A |
#9 | $22.3M | 106 | 61% | N/A | N/A |
#10 | $20.6M | 98 | -21% | N/A | N/A |
What Is Vitt?
Right now, if SaaS founders want money, they have to pitch VCs (who typically haven't even worked for a startup) or try (and fail) to get money from banks. With Vitt, get upfront, non-dilutive financing against your monthly recurring revenues. Never trade growth off against dilution again.
keywords:N/A$15M
Total Funding
5
Number of Employees
$105k
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vitt News
VITT syndrome which mimics autoimmune heparin-induced thrombocytopenia (AHIT), has a distinctive feature of thrombosis in unusual sites...
VITT is an uncommon thromboembolic event facilitated by Abs targeting platelet factor 4 (PF4) in adenoviral-vectored severe acute...
VITT has a predilection to cause thrombosis in cerebral venous sinuses, followed by splanchnic veins, particularly the portal vein, all of which...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.1M | 5 | -37% | $25M |
#2 | $0.4M | 5 | 0% | $7M |
#3 | $0.3M | 5 | 25% | N/A |
#4 | $0.5M | 5 | -58% | N/A |
#5 | $0.4M | 5 | -17% | N/A |